Joint (NASDAQ:JYNT)‘s stock had its “buy” rating restated by analysts at Maxim Group in a note issued to investors on Friday, AnalystRatings.com reports. They presently have a $25.00 price target on the stock. Maxim Group’s price target indicates a potential upside of 30.55% from the stock’s current price.
Several other research firms have also weighed in on JYNT. Zacks Investment Research raised Joint from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research report on Wednesday, October 30th. B. Riley set a $23.00 target price on Joint and gave the company a “buy” rating in a research report on Friday, August 9th. BidaskClub raised Joint from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 19th. Lake Street Capital boosted their target price on Joint from $20.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, DA Davidson reaffirmed a “buy” rating on shares of Joint in a research report on Monday, November 4th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $24.17.
Shares of NASDAQ JYNT traded down $0.66 during mid-day trading on Friday, hitting $19.15. 459,700 shares of the stock traded hands, compared to its average volume of 155,324. The firm has a 50 day simple moving average of $18.82 and a two-hundred day simple moving average of $18.09. Joint has a twelve month low of $6.51 and a twelve month high of $21.80. The company has a debt-to-equity ratio of 3.33, a current ratio of 1.04 and a quick ratio of 1.04. The company has a market cap of $275.64 million, a PE ratio of 478.75 and a beta of 1.01.
Joint (NASDAQ:JYNT) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.04 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.01. Joint had a return on equity of 114.93% and a net margin of 5.38%. The firm had revenue of $12.73 million during the quarter, compared to analyst estimates of $11.60 million. On average, equities research analysts anticipate that Joint will post 0.2 earnings per share for the current fiscal year.
A number of institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC increased its position in Joint by 100.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,547 shares of the company’s stock valued at $66,000 after buying an additional 1,780 shares in the last quarter. SG Americas Securities LLC bought a new stake in Joint in the 3rd quarter valued at about $101,000. Russell Investments Group Ltd. increased its position in Joint by 1,036.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 45,330 shares of the company’s stock valued at $845,000 after buying an additional 41,340 shares in the last quarter. Cadence Capital Management LLC bought a new stake in Joint in the 3rd quarter valued at about $2,815,000. Finally, Rhumbline Advisers increased its position in Joint by 11.7% in the 3rd quarter. Rhumbline Advisers now owns 11,481 shares of the company’s stock valued at $214,000 after buying an additional 1,201 shares in the last quarter. 64.45% of the stock is owned by institutional investors and hedge funds.
Joint Company Profile
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.